| |
NewswireTODAY - /newswire/ -
Burnaby, British Columbia, Canada, 2026/08/20 - STEMCELL Technologies has joined the Blood Profiling Atlas in Cancer (BLOODPAC), a private-public consortium working to accelerate the development, validation, and clinical adoption of liquid biopsy assays - BLOODPAC.org / Stemcell.com.
|
| |
BLOODPAC brings together leaders and experts from industry, academia, healthcare, regulatory bodies, government, and other sectors to address shared challenges and advance the development and adoption of liquid biopsy technologies through collaboration, evidence generation, data sharing, and consensus building.
As a member, STEMCELL will exchange knowledge with fellow BLOODPAC members and contribute to the development of best practices and standardized approaches that improve the quality and reproducibility of blood-based testing. Consortium members collaborate through working groups focused on areas such as analytical validation, data science, clinical implementation, and clonal hematopoiesis.
Liquid biopsy technologies offer minimally invasive approaches for detecting and analyzing cancer-associated biomarkers in blood. However, pre-analytical variability in blood collection, sample handling, processing, and storage, can influence the reliability and reproducibility of results. STEMCELL's experts in cell isolation technologies and blood sample processing will contribute scientific and technical knowledge to support the consortium's efforts to advance robust pre-analytical workflows.
"Through our membership in BLOODPAC, we look forward to both learning from leaders in the liquid biopsy field and applying our expertise in blood sample processing and biological enrichment strategies to the development of standardized pre-analytical workflows for liquid biopsy-based diagnostics," said Coral Lewis, Director, Product Management, Hematology, STEMCELL Technologies. "By working together, we can develop practical, standardized best practices that address shared pre-analytical challenges and help accelerate the clinical adoption of liquid biopsy diagnostics."
STEMCELL is proud to be a BLOODPAC member and to support collaborative advancement of the standards and evidence that underpin reliable liquid biopsy technologies to better inform medical decisions and improve patient care and outcomes.
About BLOODPAC
The Blood Profiling Atlas in Cancer (bloodpac.org) is a not-for-profit consortium working to accelerate the development, validation, and accessibility of liquid biopsy assays. BLOODPAC provides a pre-competitive collaborative infrastructure through which stakeholders from industry, academia, regulatory bodies, payers, and government agencies can share information, generate evidence, and build consensus.
About STEMCELL Technologies
STEMCELL Technologies (stemcell.com) supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
|
public.relations[.]stemcell.com 
